Healthcare Mergers, Acquisitions & Ventures Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions & Ventures Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Antisense Therapeutics Limited
Biotech firm to establish Level 1 American Depository Receipt program
November 6th, 2004
Antisense Therapeutics Limited announced that it has accepted a proposal from The Bank of New York to establish a Level 1 American Depository Receipt (ADR) program. The establishment of this ADR program will facilitate the purchase of Antisense Therapeutics shares by United States investors. This initiative is a logical extension of the company's focus on its international development, and an appropriate vehicle to leverage the high awareness of and regard for antisense technology generally and the growing international interest in Antisense Therapeutics' product development plans specifically. Mark Diamond, CEO of Antisense...
Source: Healthcare Mergers, Acquisitions & Ventures Week (2004-11-06)
|
